Outcome of cardiac surgery patients developing TRALI and control groups
| . | Transfused groups . | Nontransfused group: no ALI (n = 32) . | |
|---|---|---|---|
| TRALI (n = 16) . | No ALI (n = 32) . | ||
| Median ICU LOS, h, (IQR) | 180 (70-172)* | 45 (28-66)‡ | 38 (23-48) |
| Median hospital LOS, h, (IQR) | 381 (216-594)* | 216 (168-384)‡ | 168 (120-192) |
| Median ventilation time, h, (IQR) | 25 (21-83)* | 22 (14-40)‡ | 14 (10-18) |
| Hospital mortality, n (%) | 2 (13)† | 0 (0) | 1 (3) |
| . | Transfused groups . | Nontransfused group: no ALI (n = 32) . | |
|---|---|---|---|
| TRALI (n = 16) . | No ALI (n = 32) . | ||
| Median ICU LOS, h, (IQR) | 180 (70-172)* | 45 (28-66)‡ | 38 (23-48) |
| Median hospital LOS, h, (IQR) | 381 (216-594)* | 216 (168-384)‡ | 168 (120-192) |
| Median ventilation time, h, (IQR) | 25 (21-83)* | 22 (14-40)‡ | 14 (10-18) |
| Hospital mortality, n (%) | 2 (13)† | 0 (0) | 1 (3) |